Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

The potential health and economic impact of dexamethasone treatment for patients with COVID-19

Dexamethasone has been shown to reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment would be rolled out in the UK and globally, as well as its cost-effectiveness of implementing this intervention. We estimate that, for the UK, approximately 12,000 [4,250 - 27,000] lives could be saved by January 2021. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 [240,000 - 1,400,000] lives saved globally. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, e.g. in low and middle-income countries.

Year of Publication: 2020
Contained in: bioRxiv.org (2020) vom: 30. Juli
Language: English
Contributors: AGUAS, RICARDO | Author
Mahdi, Adam | Author
SHRETTA, RIMA | Author
Horby, Peter | Author
Landray, Martin | Author
White, Lisa J | Author
Full text access: Full text access (free access) 10.1101/2020.07.29.20164269
Links: Full Text (dx.doi.org)
ID (e.g. DOI, URN): 10.1101/2020.07.29.20164269
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 02261naa a22003852 4500
001 XBI018457959
003 DE-627
005 20200731105214.0
007 cr uuu---uuuuu
008 200731s2020 xx |||||o 00| ||eng c
024 7 |a 10.1101/2020.07.29.20164269  |2 doi 
035 |a (DE-627)XBI018457959 
035 |a (DE-599)KXPXBI018457959 
035 |a (biorXiv)10.1101/2020.07.29.20164269 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
082 0 |a 570  |q DE-84 
100 1 |a AGUAS, RICARDO  |e verfasserin  |4 aut 
245 1 0 |a The potential health and economic impact of dexamethasone treatment for patients with COVID-19 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Dexamethasone has been shown to reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment would be rolled out in the UK and globally, as well as its cost-effectiveness of implementing this intervention. We estimate that, for the UK, approximately 12,000 [4,250 - 27,000] lives could be saved by January 2021. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 [240,000 - 1,400,000] lives saved globally. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, e.g. in low and middle-income countries. 
700 1 |a Mahdi, Adam  |e verfasserin  |4 aut 
700 1 |a SHRETTA, RIMA  |e verfasserin  |4 aut 
700 1 |a Horby, Peter  |e verfasserin  |4 aut 
700 1 |a Landray, Martin  |e verfasserin  |4 aut 
700 1 |a White, Lisa J  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t bioRxiv.org  |g (2020) vom: 30. Juli 
856 4 0 |u http://dx.doi.org/10.1101/2020.07.29.20164269  |z Kostenfrei  |3 Volltext 
912 |a GBV_XBI 
936 u w |j 2020  |b 30  |c 07 
951 |a AR 
952 |j 2020  |b 30  |c 07